Merus CEO Bill Lundberg
#ASCO22: Merus looks to beat Elevation to NRG1+ summit as BLA filing approaches
CHICAGO — Merus wants to tackle a rare genomic fusion in oncology that impacts about 5,000 new patients in the US each year, and the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.